Tenofovir for the treatment of hepatitis B virus
- PMID: 19792994
- DOI: 10.1592/phco.29.10.1212
Tenofovir for the treatment of hepatitis B virus
Abstract
Tenofovir disoproxil fumarate is a nucleotide analog reverse transcriptase inhibitor recently approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus (HBV) infection in adults. Tenofovir has been available in the United States for the treatment of human immunodeficiency virus (HIV) since 2001. It blocks HBV replication in liver cells and is available as a once-daily oral formulation. The efficacy of tenofovir for the treatment of chronic HBV has been demonstrated to be superior to adefovir in randomized controlled trials, which led to its FDA approval for use in chronic HBV. Because of its potent antiviral activity, favorable safety profile, and higher barrier to the development of resistance, tenofovir should replace adefovir as a first-line monotherapy option in the treatment of HBV in monoinfected patients. In the HIV-HBV-coinfected population, tenofovir is already a preferred agent in combination with other anti-HBV agents (lamivudine or emtricitabine), which are cotreatments for HIV as well. In addition, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other therapies for chronic HBV, including lamivudine and adefovir.
Similar articles
-
Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.Expert Rev Anti Infect Ther. 2010 Oct;8(10):1079-92. doi: 10.1586/eri.10.91. Expert Rev Anti Infect Ther. 2010. PMID: 20954872 Review.
-
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.J Infect Dis. 2004 Apr 1;189(7):1185-92. doi: 10.1086/380398. Epub 2004 Mar 12. J Infect Dis. 2004. PMID: 15031786 Clinical Trial.
-
Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.J Viral Hepat. 2005 Jul;12(4):364-72. doi: 10.1111/j.1365-2893.2005.00620.x. J Viral Hepat. 2005. PMID: 15985006 Clinical Trial.
-
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.AIDS. 2006 Oct 3;20(15):1951-4. doi: 10.1097/01.aids.0000247116.89455.5d. AIDS. 2006. PMID: 16988516 Clinical Trial.
-
[Treatment of chronic hepatitis B in HIV co-infected patients].Gastroenterol Clin Biol. 2008 Jan;32(1 Pt 2):S20-4. doi: 10.1016/S0399-8320(08)73261-5. Gastroenterol Clin Biol. 2008. PMID: 18662606 Review. French.
Cited by
-
Human health implications of emerging diseases and the current situation in India's vaccine industry.Sci One Health. 2023 Oct 29;2:100046. doi: 10.1016/j.soh.2023.100046. eCollection 2023. Sci One Health. 2023. PMID: 39077045 Free PMC article. Review.
-
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.World J Gastroenterol. 2018 Apr 28;24(16):1708-1724. doi: 10.3748/wjg.v24.i16.1708. World J Gastroenterol. 2018. PMID: 29713126 Free PMC article. Review.
-
Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Ann Hematol. 2021 Feb;100(2):321-336. doi: 10.1007/s00277-020-04297-8. Epub 2020 Oct 20. Ann Hematol. 2021. PMID: 33079221 Free PMC article. Review.
-
Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir.Pharmacogenomics. 2019 Jan;20(2):105-111. doi: 10.2217/pgs-2018-0140. Epub 2019 Jan 10. Pharmacogenomics. 2019. PMID: 30628547 Free PMC article. Review.
-
Effectiveness and Safety of Low Dose of Tenofovir Disoproxil Fumarate in Malagasy Patients with Chronic Hepatitis B.Biomed Res Int. 2022 May 31;2022:1654620. doi: 10.1155/2022/1654620. eCollection 2022. Biomed Res Int. 2022. PMID: 35686236 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources